As peptide therapies gain traction in Silicon Valley biohacking circles, California Trim Clinic warns that gray-market “research peptides” sourced from overseas suppliers may carry significant risks. The physician-led telehealth clinic says many of the same compounds attracting attention online can instead be prescribed safely through licensed U.S. compounding pharmacies under medical supervision.

The sudden shutdown of Peptide Sciences, one of the largest research peptide vendors in the United States, signals a turning point in the peptide market. For years, thousands of individuals sourced compounds like Semaglutide, Tirzepatide, and BPC-157 through online vendors operating outside the traditional medical system. California Trim Clinic says the closure confirms a regulatory shift that has been building for years — one that is rapidly moving peptide therapies out of the gray market and into physician-supervised care delivered through licensed prescribers and medications prepared by FDA-regulated U.S. compounding pharmacies, the same sourcing model used across the clinic’s metabolic and peptide therapy programs at California Trim Clinic.